Zde se nacházíte:
Informace o publikaci
Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration
Autoři | |
---|---|
Rok publikování | 2022 |
Druh | Článek v odborném periodiku |
Časopis / Zdroj | European Journal of Cancer |
Fakulta / Pracoviště MU | |
Citace | |
www | https://www.sciencedirect.com/science/article/pii/S0959804921011709?via%3Dihub |
Doi | http://dx.doi.org/10.1016/j.ejca.2021.10.016 |
Klíčová slova | Paediatric oncology; CAR T-cell; Adoptive cellular immunotherapy; Paediatric Strategy Forum; Drug development; Cancer therapeutics |
Popis | The seventh multi-stakeholder Paediatric Strategy Forum focused on chimeric antigen receptor (CAR) T-cells for children and adolescents with cancer. The development of CAR T-cells for patients with haematological malignancies, especially B-cell precursor acute lymphoblastic leukaemia (BCP-ALL), has been spectacular. However, currently, there are scientific, clinical and logistical challenges for use of CAR T-cells in BCP-ALL and other paediatric malignancies, particularly in acute myeloid leukaemia (AML), lymphomas and solid tumours. The aims of the Forum were to summarise the current landscape of CAR T-cell therapy development in paediatrics, too identify current challenges and future directions, with consideration of other immune effector modalities and ascertain the best strategies to accelerate their development and availability to children. |